Investigating the effect of diet consumption based on high adherence to the global diet quality score on the control of sugar factors, mental health and anthropometric indicators in patients with type 2 diabetes

Investigating the effect of consuming a diet based on high adherence to the Global Diet Quality Score (GDQS) with a standard diet on the control of sugar factors, mental health and anthropometric indicators in patients with type 2 diabetes: a randomized clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210427051098N4

Enrollment

134

Registered

2023-12-01

Start date

2023-12-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group:In the diet group based on the GDQS index, people with type 2 diabetes were given GDQS diet training for 3 sessions (the first week before the start of the intervent

But if the body mass index is more than 25, the adjusted weight of people according to the body mass index of 25 is used to calculate energy. The weight loss phase for overweight and obese people ends

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Participants with type 2 diabetes Fasting blood glucose level = 126 mg/dL The two-hour plasma glucose level =200 mg/dL Consumption of oral hypoglycemic medications Body mass index (BMI) = 40 kg/m2 Completion of informed consent

Exclusion criteria

Exclusion criteria: Uncontrolled diabetes (HbA1C more than 9 mg/dl) Suffering from diabetic nephropathy History of ischemic heart disease pregnancy Lactation History of hospitalization for the treatment of heart disease during the last 6 months History of cancer treatment in the last 5 years Suffering from proteinuria History of steroid treatment during the last 3 months Suffering from thyroid disease History of lung disease and compliance with special diet Suffering from hepatitis Suffering from gastrointestinal disease Suffering from pancreatitis Suffering from inflammatory bowel disease Bowel resection Infected with AIDS Suffering from acute mental disorders Suffering from Cushing's syndrome Alcohol consumption Drug abuse Taking thiazide diuretics Taking antidepressants

Design outcomes

Primary

Measure	Time frame
HBA1C. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood test.;Fasting Plasma Glucose (FPG). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Insulin. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Insulin resistance index. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Formula.;Triacyl glyceride (TG). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Total cholesterol. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;High Density Lipoprotein (HDL). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Low Density Lipoprotein (LDL). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Anxiety. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Beck validated questionnaire.;Depression. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Beck validated questionnaire.;Sleep quality. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Pittsburgh validated questionnaire.;Quality of Life. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: SF-36 validated questionnaire.	—

Measure

Time frame

HBA1C. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood test.;Fasting Plasma Glucose (FPG). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Insulin. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Insulin resistance index. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Formula.;Triacyl glyceride (TG). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Total cholesterol. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;High Density Lipoprotein (HDL). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Low Density Lipoprotein (LDL). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Blood sample.;Anxiety. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Beck validated questionnaire.;Depression. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Beck validated questionnaire.;Sleep quality. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Pittsburgh validated questionnaire.;Quality of Life. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: SF-36 validated questionnaire.

—

Secondary

Measure	Time frame
Height. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Tape measure.;Weight. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Weighting scale.;Body Mass Index (BMI). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Body composition analyzer.;Waist circumference. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Tape measure.;Hips circumference. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Tape measure.;Fat mass. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Body composition analyzer.;Fat free mass. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Body composition analyzer.;Blood pressure. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Measurement of systolic and diastolic blood pressure (mmHg).	—

Measure

Time frame

Height. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Tape measure.;Weight. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Weighting scale.;Body Mass Index (BMI). Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Body composition analyzer.;Waist circumference. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Tape measure.;Hips circumference. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Tape measure.;Fat mass. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Body composition analyzer.;Fat free mass. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Body composition analyzer.;Blood pressure. Timepoint: Before the intervention, 12 weeks after the intervention. Method of measurement: Measurement of systolic and diastolic blood pressure (mmHg).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Bagherpour

Yazd University of Medical Sciences

sarabagherpour1376@gmail.com+98 35 3149 2228

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026